Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

 Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

Lilly Acquires Hydra Biosciences with its Pre-Clinical Pain Program for Chronic Pain Syndromes

Shots:
  • Lilly to acquire Hydra, in all stock transaction with its all pre-clinical pain program of TRPA1 antagonists
  • The focus of the acquisition is to develop treatments for chronic pain and understand TRP pathway in pain signaling, further initiate clinical trials
  • Hydra’s Transient Receptor Potential (TRP) channel program consists of group of non-selective
    cation channels indicated for the treatment of pain, inflammation and hypertension

Click here to read full press release/ article | Ref: Eli Lilly | Image:  PM Live

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post